整合TP53突变的套细胞淋巴瘤新型预后指数MIPI53的开发与验证
研究基于143例新诊断套细胞淋巴瘤患者,将TP53突变与LDH、ECOG状态和年龄整合,开发MIPI53指数。低、中、高危组5年PFS分别为83.1%、35.4%和12.0%(p<0.0001),5年OS分别为92.1%、80.5%和33.8%(p<0.0001)。外部验证(FIL MCL0208试验)证实模型稳健性(OS的c-index 0.732,AIC 296.2)。
要点
- MIPI53整合TP53突变、LDH、ECOG和年龄,将MCL分为低、中、高危三组。
- 三组5年PFS和OS差异显著,高危组5年OS仅33.8%。
- 简化版sMIPI53保持高预测准确性,训练集c-index 0.819,外部集0.730。
核心结论
- MIPI53指数通过整合遗传与临床变量,有效将MCL患者分层为不同预后组,增强结局预测。
研究设计与样本
- 研究分析143例新诊断MCL患者的真实世界队列,评估TP53突变状态及临床生物学标志。
- 通过bootstrap进行内部验证,并使用FIL MCL0208试验数据进行外部验证。
主要发现
- 低、中、高危组5年PFS分别为83.1%、35.4%和12.0%(p<0.0001)。
- 低、中、高危组5年OS分别为92.1%、80.5%和33.8%(p<0.0001)。
- 外部验证显示OS的c-index为0.732,AIC为296.2。
- 简化版sMIPI53在训练集c-index为0.819、AIC为404.5,外部集c-index为0.730、AIC为296.7。
临床怎么用
- MIPI53可用于新诊断MCL患者的预后分层,辅助识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a clinically heterogeneous disease with varying treatment responses and outcomes. Despite the utility of the Mantle Cell Lymphoma International Prognostic Index (MIPI), its predictive capacity can be enhanced by integrating genetic markers such as TP53 mutations. We analysed 143 newly diagnosed MCL patients from a real-world cohort, assessing TP53 mutational status, clinical and biological markers. We developed the MIPI53 index by incorporating TP53 mutations, lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) status and age. Internal validation was performed via bootstrapping, and external validation was conducted with data from the fondazione Italiana Linfomi (FIL) MCL0208 trial. Patients were stratified into low-, intermediate- and high-risk groups, showing significant differences in 5-year progression-free survival (PFS) (83.1%, 35.4% and 12.0%, respectively; p < 0.0001) and 5-year overall survival (OS) (92.1%, 80.5% and 33.8%, respectively; p < 0.0001). External validation confirmed the robustness of the model (c-index: 0.732; akaike information criterion, AIC: 296.2 according to OS). A simplified version (sMIPI53) was developed, maintaining high predictive accuracy in both training (c-index: 0.819; AIC: 404.5) and external cohort (c-index: 0.730; AIC: 296.7). The MIPI53 index effectively stratifies MCL patients into prognostic groups by integrating genetic and clinical variables to enhance outcome prediction.
引用
- Bastos-Boente M, Medina-Herrera A, Navarro-Bailón A, et al. Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53). Br J Haematol. 2026. PMID: 42134850. doi:10.1111/bjh.70535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。